［1］TORRE LA，SIEGEL ＲL，WARD EM，et al．Global cancer incidence and mortality rates and trends-an update［J］． Cancer Epidemiol Biomarkers Prev，2016，25：16-27.
［2］BELANI CP.Epidermal growth factor receptor mutations：A new insight［J］.Clinical Lung Cancer，2004，5(6)：328.
［3］TONY SM，YI LW，SUMITRA T，et al．Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma［J］.The Journal of Evidence-Based Medicine，2009，361(10)：947.
［4］李芸，余秉翔.基因芯片技术在肺癌研究中的应用［J］.解放军医学院学报，2010，31(4)：401-403.
LI Y，YU BX.Application of gene chip technology in lung cancer research［J］.Journal of Chinese PLA Medical College，2010，31(4)：401-403.
［5］ROTOLO F，ZHU CQ，BRAMBILLA E，et al.Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer［J］.Transl Lung Cancer Res，2018，7：416-427.
［6］XUE L，FEI JJ，SONG Y，et al.Visual DNA microarray for detection of epidermal growth factor receptor (EGFR) gene mutations［J］.Scandinavian Journal of Clinical & Laboratory Investigation，2014，74(8)：693-699.
［7］BUMGARNER R.Overview of DNA microarrays：Types，applications，and their future［J］.Current Protocols in Molecular Biology，2013，101(01):96.
［8］CRONIN M，ROSS JS.Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology［J］.Biomarkers in Medicine，2011，5(3)：293-305.
［9］MORGANTI S，TARANTINO P，FERRARO E，et al.Complexity of genome sequencing and reporting：Next generation sequencing(NGS) technologies and implementation of precision medicine in real life［J］.Crit Rev Oncol Hematol，2019，133：171-182.
［10］WEN SW，DAI L，WANG L，et al.Genomic signature of driver genes identified by target next-generation sequencing in chinese non-small cell lung cancer［J］.Oncologist，2019，24：e1070-e1081.
［11］DONO M，DE LUCA G，LASTRAIOLI S，et al.Tag-based next generation sequencing：A feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients［J］.Mol Med，2019，25：15.
［12］YOUSSEF O，KNUUTTILA A，PIIRIL P，et al.Hotspot mutations detectable by next-generation sequencing in exhaled breath condensates from patients with lung cancer［J］.Anticancer Res，2018，38：5627-5634.
［13］DE BIASE D，VISANI M，MALAPELLE U，et al.Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy)［J］.PLoS One，2013，8：e83607.
［14］VAN DIJK E，JASZCZYSZYN Y，NAQUIN D，et al.The third revolution in sequencing technology［J］.Trends Genet，2018，34：666-681.
［15］CERNOMAZ AT，MACOVEI II，PAVEL I，et al.Comparison of next generation sequencing，SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment［J］.BMC Pulmonary Medicine，2016，16(1)：88.
［16］LIU J，ZHAO R，ZHANG J，et al.ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens［J］.Journal of Cancer Research & Clinical Oncology，2015，141(2)：221-227.
［17］MOK T，WU YL，LEE JS，et al.Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy［J］.Clinical Cancer Research，2015，21(14)：3196-3203.
［18］ZHU LC，ZHANG SR，XUN YP，et al.Comparison of the amplification refractory mutation system，super amplification refractory mutation system，and droplet digital PCR for T790 M mutation detection in non-small cell lung cancer after failure of tyrosine kinase inhibitor treatment［J］.Pathol Oncol Res，2018，24：843-851.
［19］SU F，FU YY，WU Q，et al.High concordance of EGFR mutation status between sputum and corresponding tissue specimens of late-stage lung cancers using amplification refractory mutation system-PCR［J］.Int J Clin Exp Pathol，2018，11：2683-2690.
［20］MARKOU A，TZANIKOU E，LADAS I，et al.Nuclease-assisted minor allele enrichment using overlapping probes-assisted amplification-refractory mutation system：An approach for the improvement of amplification-refractory mutation system-polymerase chain reaction specificity in liquid biopsies［J］.Anal Chem，2019，91：13105-13111.
［21］SONG C，LIU YB，FONTANA R，et al.Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment［J］.Nucleic Acids Res，2016，44：e146.
［22］ARDAKANI NM，GIARDINA T，GRIEU-IACOPETTA F，et al.Detection of epidermal growth factor receptor mutations in lung adenocarcinoma：Comparing cobas 4800 EGFR assay with sanger bidirectional sequencing［J］.Clin Lung Cancer，2016，17：e113-e119.
［23］LOPEZ-RIOS F，ANGULO B，GOMEZ B，et al.Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer［J］.J Clin Pathol，2013，66(5)：381-385.
［24］WU YL，LEE V，LIAM CK，et al.Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE，FASTACT-2，and ASPIRATION studies［J］.Lung Cancer，2018，126：1-8.
［25］SATOUCHI M，TANAKA H，YOSHIOKA H，et al.Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas EGFR mutation test［J］.Lung Cancer，2017，111：190.
［26］BUDER A，SETINEK U，HOCHMAIR MJ，et al.EGFR mutations in cell-free plasma DNA from patients with advanced lung adenocarcinoma：Improved detection by droplet digital PCR［J］.Target Oncol，2019，14：197-203.
［27］JENKINS S，YANG J，RAMALINGAM S，et al.Plasma ctDNA analysis for detection of EGFR T790M mutation in patients(pts) with EGFR mutation-positive advanced non-small cell lung cancer(aNSCLC)［J］.Journal of Thoracic Oncology，2016，11(4)：S153-S154.
［28］冯兆民，舒跃龙.数字PCR技术及其应用进展［J］.病毒学报，2017，33(01)：103-107.
FENG ZM，SHU YL.Progress of digital PCR technology and its application［J］.J Virol，2017，33(01)：103-107.
［29］DENIS JRA，NECTOUX J，LAMY PJ，et al.Development of digital PCR molecular tests for clinical practice：principles，practical implementation and recommendations［J］.Ann Biol Clin(Paris)，2018，76：505-523.
［30］GU J，ZANG W，LIU B，et al.Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients：A cross-platform comparison study［J］.Oncotarget，2017，8(40)：67810-67820.
［31］SREEJITH KR，OOI CH，JIN J，et al.Digital polymerase chain reaction technology-recent advances and future perspectives［J］.Lab Chip，2018，18：3717-3732.
［32］OXNARD GR，PAWELETZ CP，KUANG Y，et al.Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA［J］.Clin Cancer Res，2014，20(6)：1698-1705.
［33］LI R，YE SB，HE Y，et al.Detection of epidermal growth factor receptor gene mutations in different types of non-small cell lung cancer by droplet digital PCR and amplification refractory mutation system［J］.Chinese J Pathol，2017，46(11)：764-768.
［34］OLMEDILLAS-LóPEZ S，GARCíA-ARRANZ M，GARCíA-OLMO D.Current and emerging applications of droplet digital PCR in oncology［J］.Mol Diagn Ther，2017，21：493-510.
［35］CUI CH，SHU W，LI PN.Fluorescence in situ hybridization：cell-based genetic diagnostic and research applications［J］.Front Cell Dev Biol，2016，4：89.
［36］LUK PP，SELINGER CI，MAHAR A，et al.Biomarkers for ALK and ROS1 in lung cancer：immunohistochemistry and fluorescent in situ hybridization［J］.Arch Pathol Lab Med，2018，142：922-928.
［37］GINESTET F，LAMBROS L，LE FLAHEC G，et al.Evaluation of a Dual ALK/ROS1 fluorescent in situ hybridization test in non-small-cell lung cancer［J］.Clin Lung Cancer，2018，19：e647-e653.
［38］TANG ZY，WANG L，TANG GL，et al.Fluorescence in situ hybridization(FISH) for detecting anaplastic lymphoma kinase(ALK) rearrangement in lung cancer：clinically relevant technical aspects［J］.International Journal of Molecular Sciences，2019，20(16)：3939.
［39］VOLLBRECHT C，LENZE D，HUMMEL M，et al.RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance［J］.BMC Cancer，2018，18：1158.
［40］LINDEMAN NI，CAGLE PT，AISNER DL，et al.Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors：guideline from the college of american pathologists，the international association for the study of lung cancer，and the association for molecular pathology［J］.J Thorac Oncol，2018，13：323-358.